BeiGene Brukinsa gets approval in Canada for blood cancer subtype

OGphoto/iStock via Getty Images

• BeiGene (NASDAQ:BGNE) medicine Brukinsa was approved by Health Canada to treat adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.
• The company said it was the third approved indication for Brukinsa (zanubrutinib) in Canada, following mantle cell lymphoma and Waldenström’s macroglobulinemia.
• The approval was backed by data from the MAGNOLIA trial and the BGB-3111-AU-003 (NCT02343120) study.
• In February, Brukinsa was approved in Switzerland to treat certain adult patients with Waldenström’s macroglobulinemia.
• MZL is a group of slow growing non-Hodgkin’s lymphoma (NHL) B-cell lymphomas.